Events

 

UPCOMING EVENTS

 

January 30-31, 2018, San Diego, CA

ImmunoTX Summit by GTCbio

Link: https://www.gtcbio.com/conferences/immunotx-summit-agenda

 

March 8-9, 2018, London, UK

9th Molecular Immunology & Immunogenetics Congress

Link: https://molecularimmunology.conferenceseries.com/

 

March 27-28, 2018, San Diego, CA

Biomarker Summit 2018 by GTCbio

Link: https://www.gtcbio.com/conferences/biomarkers-summit-agenda

 

April 14-18, 2018, Chicago, IL

AACR Annual Meeting 2018

Link: https://www.asco.org/2018-asco-annual-meeting

 

May 4-8, 2018, Austin, Texas

Immunology 2018 AAI Annual Meeting

Link: http://www.immunology2018.org/

 

May 22-24, 2018, Lisbon, Portugal

Biomarkers for Immunotherapy Conference as part of the Molecular Diagnostocs Europe

Link: http://www.moleculardxeurope.com

 

June 1-5, 2018, Chicago, IL

2018 Asco Annual Meeting

Link: http://am.asco.org

 

June 18-22, 2018

World Clinical Congress "Cancer Immunotherapy and Combinations"

Link: http://www.worldpreclinicalcongress.com/Cancer-Immunotherapy-Combinations/

 

August 28-29, 2018, San Diego, CA

7th Cancer Therapeutics & Partnering Summit by GTCbio

Link: https://www.gtcbio.com/conferences/novel-cancer-therapeutics-summit/

 

October 19-23, 2018, Munich, Germany

ESMO 2018 Congress

Link: http://www.esmo.org/Conferences/ESMO-2018-Congress

 

October 24-27, 2018, Lisbon, Portugal

18th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2018)

Link: http://www.esid.kenes.com/2018

 

November 7-11, 2018, DC

SITC

Link: http://www.sitcancer.org/education/annualmeeting

 

PREVIOUS EVENTS

 

October 19 - 20, 2017, Boston, MA

Novel Cancer Therapeutics Summit

Link: https://www.gtcbio.com/conferences/cancer-therapeutics-summit-overview?alias=cancer-therapeutics-summit

 

September 28 - 29, 2017, San Diego, CA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the 6th Cancer Therapeutics & Partnering Summit by GTCbio.

Link: https://www.gtcbio.com/conferences/novel-cancer-therapeutics-summit/

 

September 11 - 14, 2017, Edinburgh, Scotland

Christoph Sachsenmaier, PhD, VP Strategic Business Development, Epiontis, attended the 18th Meeting of the European Society for Immunodeficiencies (ESID 2017).

Link: http://esid2017.kenes.com/

 

September 8 - 12, 2017, Madrid, Spain

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended the ESMO 2017 Congress.

Link: http://www.esmo.org/Conferences/ESMO-2017-Congress

 

August 15 - 18, 2017, Washington, D.C.

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the Next Generation Diagnostics Summit 2017.

Link: http://www.nextgenerationdx.com/

 

June 13 - 14, 2017, Boston, MA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the World Preclinical Congress "Cancer Immunotherapy and Combinations".

Link: http://www.worldpreclinicalcongress.com/Cancer-Immunotherapy-Combinations/

 

June 2 - 6, 2017, Chicago, Il

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended the 2017 ASCO Annual Meeting.

Link: http://am.asco.org

 

 May 12 - 16, 2017, Washington, D.C.

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended Immunology 2017 AAI Annual Meeting.

Link: http://www.immunology2017.org/

 

April 12 - 13, 2017, Lisbon, Portugal

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the Biomarkers for Immunotherapy Conference as part of the Molecular Diagnostics Europe.

Link: http://www.moleculardxeurope.com/Immunotherapy-Biomarkers/

 

March 20 - 22, 2017, San Diego, CA

Thomas Kleen, PhD, Exec. VP Immune Monitoring at Epiontis, spoke at the Biomarker Summit 2017
by GTCbio.

Link: https://www.gtcbio.com/conferences/biomarkers-summit-agenda

 

February 6 - 7, 2017, San Diego, CA

Ulrich Hoffm├╝ller, PhD, MBA, CBO and Founder of Epiontis, spoke at the ImmunoTX Summit
by GTCbio.

Link: https://www.gtcbio.com/conferences/immunotx-summit-agenda

 

 

  1. Privacy Statement: Your phone number or email address will be exclusively used to contact you and will not be given to any third party.